---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-106936"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2022-10-07T23:59:59+00:00"
generated_at: "2026-06-23T04:44:50.741621+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Replimune secures $200M non-dilutive debt facility from Hercules Capital

## Summary
- $200M term loan; $30M funded at closing, $30M available by Sep 30, 2023.
- Up to $115M available upon clinical/regulatory/commercial milestones; $25M subject to Hercules consent.
- Interest: floating cash rate (greater of 7.25% or Prime+1.75% capped at 7.25%) plus 1.50% PIK.
- At least 48 months interest-only, extendable to 60 months on milestone achievement; matures Oct 2027.
- Proceeds extend cash runway into 2025 ahead of CERPASS/IGNYTE trial catalysts and commercial prep.

## SEC filing metadata
- accession: 0001104659-22-106936
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2022-10-07T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/0001104659-22-106936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/tm2227789d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-106936
- JSON: https://secwatch.observer/filing/0001104659-22-106936.json
- Plain text: https://secwatch.observer/filing/0001104659-22-106936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.